UNSPSC 51295108: Fantridone hydrochloride

This classification denotes an antidepressant agent with the molecular formula C18H20N2O.CLH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DU65LYP662. The term fantridone hydrochloride is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule fantridone hydrochloride under HS 29337900 and SITC 51561. As of Q4 2014, FANTRIDONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Fantridone hydrochloride bears US NLM identifiers UMLS ID C1880733 and NCI Concept Code C65619.

SMILES: CN(C)CCCN1C2CCCCC2C3CCCCC3C1=O.O.CL.

UNSPSC 51295108 Fantridone hydrochloride is a Commodity code that covers pharmaceutical products, though recent state and local solicitations show minimal activity specific to this substance and instead reflect broader pharmaceutical procurement across multiple therapeutic categories and delivery models. State and local issuing bodies soliciting under pharmaceutical codes purchase generic multi-source drugs, naloxone and drug-deactivation systems, and direct-to-manufacturer prescription programs through various contracting mechanisms. The issuing bodies include state health and human services departments, county health authorities, and cooperative purchasing alliances spanning multiple jurisdictions. Vendors must typically maintain FDA compliance, current Good Manufacturing Practices (cGMP) certification, Drug Supply Chain Security Act (DSCSA) adherence, and commercial general liability insurance; many procurements require E-Verify compliance and drug-free workplace certification as a condition of award.

Recent activity shows sparse direct opportunities under this specific code. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) posted January 20, 2026, with a due date of March 26, 2026, for generic multi-source pharmaceuticals and OTC products across Minnesota and Oregon, requiring manufacturers to supply through authorized wholesalers and emphasizing price competitiveness as 75 percent of evaluation weight. Seminole County, Florida issued an IFB (IFB60459723LAS) posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs, signaling potential future pharmaceutical procurement by the state. Geographic activity centers on Minnesota, Texas, and Florida, with the MMCAP procurement serving a broader multistate region. The code shows limited recent activity directly aligned to fantridone hydrochloride procurement.